Skip to main content
SpringerLink
Log in

Gastric Acid Secretions, Treatments, and Nutritional Consequences

  • Chapter
Book cover Preventive Nutrition

Part of the book series: Nutrition and Health ((NH))

  • 2481 Accesses

Abstract

The objectives of this chapter are to provide an overview of the roles of gastric acid in health and disease, to discuss the use of acid-suppressive therapies that are used to mitigate prevalent acid-related symptoms and/or diseases and to review potential detrimental nutritional and related consequences. Particular emphasis is placed on reviewing the body of evidence related to drug–drug, and drug–nutrient interactions, and further, the nutritional consequences of gastric acid imbalance as it is related to vitamin and mineral status. Finally, there is a brief discussion related to the consequences of reduced gastric acid with regard to disturbances in the natural bacterial population and balance (microbiome) throughout the gastrointestinal tract.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chu S, Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2013;29(6):636–41.

    Article  PubMed  CAS  Google Scholar 

  2. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60.

    Article  PubMed  CAS  Google Scholar 

  3. Pohl D, Fox M, Fried M, et al. Do we need gastric acid? Digestion. 2008;77(3-4):184–97.

    Article  PubMed  CAS  Google Scholar 

  4. Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2007;23(6):595–601.

    Article  PubMed  CAS  Google Scholar 

  5. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol. 2003;65:103–31.

    Article  PubMed  CAS  Google Scholar 

  6. Hirschowitz BI, Fineberg N, Wilcox CM, et al. Costs and risks in the management of patients with gastric acid hypersecretion. J Clin Gastroenterol. 2010;44(1):28–33.

    Article  PubMed  Google Scholar 

  7. Zaki M, Coudron PE, McCuen RW, et al. H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am J Physiol Gastrointest Liver Physiol. 2013;304(8):G715–22.

    Article  PubMed  CAS  Google Scholar 

  8. Orlando RC. The integrity of the esophageal mucosa. Balance between offensive and defensive mechanisms. Best Pract Res Clin Gastroenterol. 2010;24(6):873–82.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tobey NA, Hosseini SS, Caymaz-Bor C, et al. The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol. 2001;96(11):3062–70.

    Article  PubMed  CAS  Google Scholar 

  10. Roberts NB. Review article: human pepsins—their multiplicity, function and role in reflux disease. Aliment Pharmacol Ther. 2006;24 Suppl 2:2–9.

    Article  PubMed  CAS  Google Scholar 

  11. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20.

    Article  PubMed  Google Scholar 

  12. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383–91.

    Article  PubMed  Google Scholar 

  13. Pace F, Bazzoli F, Fiocca R, et al. The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2009;21:304–18.

    Article  Google Scholar 

  14. Sawaya RA, Macgill A, Parkman HP, et al. Use of the Montreal global definition as an assessment of quality of life in reflux disease. Dis Esophagus. 2012;25(6):477–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72(4):437–45.

    Article  PubMed  CAS  Google Scholar 

  16. Minatsuki C, Yamamichi N, Shimamoto T, et al. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013;8(7):e69891.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98(7):1487–93.

    Article  PubMed  Google Scholar 

  18. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Friedenberg FK, Makipour K, Palit A, et al. Population-based assessment of heartburn in urban Black Americans. Dis Esophagus. 2013;26(6):561–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Cohen E, Bolus R, Khanna D, et al. GERD symptoms in the general population: prevalence and severity versus care-seeking patients. Dig Dis Sci. 2014;59(10):2488–96.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Goh KL, Choi MG, Hsu WP, et al. Unmet treatment needs of gastroesophageal reflux disease in Asia: gastroesophageal reflux disease in Asia Pacific Survey. J Gastroenterol Hepatol. 2014;29(12):1969–75.

    Article  PubMed  Google Scholar 

  22. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011;17(1):14–27.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ercelep OB, Caglar E, Dobrucali A. The prevalence of gastroesophageal reflux disease among hospital employees. Dis Esophagus. 2014;27(5):403–8.

    Article  PubMed  CAS  Google Scholar 

  24. Chou PH, Lin CC, Lin CH, et al. Prevalence of gastroesophageal reflux disease in major depressive disorder: a population-based study. Psychosomatics. 2014;55(2):155–62.

    Article  PubMed  Google Scholar 

  25. Sobrino-Cossio S, Lopez-Alvarenga JC, Remes-Troche JM, et al. Proton pump inhibitors in gastroesophageal reflux disease: “a custom-tailored therapeutic regimen”. Rev Esp Enferm Dig. 2012;104(7):367–78.

    Article  PubMed  Google Scholar 

  26. Thoua NM, Khoo D, Kalantzis C, et al. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2008;27(5):396–403.

    Article  PubMed  CAS  Google Scholar 

  27. deBortoli N, Martinucci I, Bellini M, et al. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013;19(35):5787–97.

    Article  Google Scholar 

  28. Armstrong D. Systematic review: persistence and severity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;28(7):841–53.

    PubMed  CAS  Google Scholar 

  29. Fiedorek S, Tolia V, Gold BD, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2005;40(3):319–27.

    Article  PubMed  CAS  Google Scholar 

  30. Fedorak RN, van Veldhuyzen ZS, Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010;24(7):431–4.

    PubMed  PubMed Central  Google Scholar 

  31. Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;27(3):249–56.

    Article  PubMed  CAS  Google Scholar 

  32. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–87.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43(1):161–73.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kleiman DA, Beninato T, Bosworth BP, et al. Early referral for esophageal pH monitoring is more cost-effective than prolonged empiric trials of proton-pump inhibitors for suspected gastroesophageal reflux disease. J Gastrointest Surg. 2014;18(1):26–33.

    Article  PubMed  Google Scholar 

  35. Masclee GM, Sturkenboom MC, Kuipers EJ. A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs Aging. 2014;31(4):263–82.

    Article  PubMed  CAS  Google Scholar 

  36. Shmuely H, Katicic M, Filipec KT, et al. Helicobacter pylori and nonmalignant diseases. Helicobacter. 2012;17 Suppl 1:22–5.

    Article  PubMed  Google Scholar 

  37. den Hollander WJ, Sostres C, Kuipers EJ, et al. Helicobacter pylori and nonmalignant diseases. Helicobacter. 2013;18 Suppl 1:24–7.

    Article  Google Scholar 

  38. McColl KE, How I, Manage H. Pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol. 2009;104(1):190–3.

    Article  PubMed  Google Scholar 

  39. Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18.

    Article  PubMed  CAS  Google Scholar 

  40. Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344, e372.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Raghunath AS, O’Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22 (Suppl 1):55–63.

    Article  PubMed  CAS  Google Scholar 

  42. Masaoka T, Suzuki H, Hibi T. Gastric epithelial cell modality and proton pump inhibitor. J Clin Biochem Nutr. 2008;42(3):191–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Raghunath AS, Hungin AP, Mason J, et al. Helicobacter pylori eradication in long-term proton pump inhibitor users in primary care: a randomized controlled trial. Aliment Pharmacol Ther. 2007;25(5):585–92.

    Article  PubMed  CAS  Google Scholar 

  44. McColl KE. Effect of proton pump inhibitors on vitamins and iron. 2008.

    Google Scholar 

  45. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy. 2003;23(4):460–71.

    Article  PubMed  CAS  Google Scholar 

  46. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800–11.

    Article  PubMed  CAS  Google Scholar 

  47. Shin JM, Vagin O, Munson K, et al. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65(2):264–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998–1004.

    PubMed  Google Scholar 

  49. Yang YX. Chronic proton pump inhibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473–9.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98(1):4–19.

    Article  PubMed  CAS  Google Scholar 

  51. Ward EK, Schuster DP, Stowers KH, et al. The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2014;24(9):1567–71.

    Article  PubMed  Google Scholar 

  52. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012;5(4):219–32.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Herzig SJ, Vaughn BP, Howell MD, et al. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med. 2011;171(11):991–7.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Morneau KM, Reaves AB, Martin JB, et al. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel. J Manag Care Pharm. 2014;20(2):187–93.

    PubMed  Google Scholar 

  55. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010;16(9):e228–34.

    PubMed  Google Scholar 

  56. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28(6):615–20.

    Article  PubMed  CAS  Google Scholar 

  57. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28.

    Article  PubMed  Google Scholar 

  58. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102(3):668–85.

    Article  PubMed  Google Scholar 

  59. Tran T, Lowry AM, El Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25(2):143–53.

    PubMed  CAS  Google Scholar 

  60. Nam SY, Choi IJ, Ryu KH, et al. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women. Gastroenterology. 2010;139(6):1902–11.

    Article  PubMed  Google Scholar 

  61. Anggiansah R, Sweis R, Anggiansah A, et al. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;37(5):555–63.

    Article  PubMed  CAS  Google Scholar 

  62. Hampel H, Abraham NS, El Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.

    Article  PubMed  Google Scholar 

  63. Mion F, Dargent J. Gastro-oesophageal reflux disease and obesity: pathogenesis and response to treatment. Best Pract Res Clin Gastroenterol. 2014;28(4):611–22.

    Article  PubMed  Google Scholar 

  64. Bruce MG, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter. 2008;13 Suppl 1:1–6.

    Article  PubMed  Google Scholar 

  65. Ierardi E, Goni E, Losurdo G, et al. Helicobacter pylori and nonmalignant diseases. Helicobacter. 2014;19 Suppl 1:27–31.

    Article  PubMed  CAS  Google Scholar 

  66. Kwok A, Lam T, Katelaris P, et al. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf. 2008;7(3):271–81.

    Article  PubMed  CAS  Google Scholar 

  67. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis. 2008;40(8):619–26.

    Article  PubMed  CAS  Google Scholar 

  68. Moschos JM, Kouklakis G, Vradelis S, et al. Patients with established gastro-esophageal reflux disease might benefit from eradication. Ann Gastroenterol. 2014;27(4):352–6.

    PubMed  PubMed Central  Google Scholar 

  69. Permin H, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter infection. Helicobacter. 2005;10 Suppl 1:21–5.

    Article  PubMed  CAS  Google Scholar 

  70. Lopetuso LR, Scaldaferri F, Franceschi F, et al. The gastrointestinal microbiome—functional interference between stomach and intestine. Best Pract Res Clin Gastroenterol. 2014;28(6):995–1002.

    Article  PubMed  CAS  Google Scholar 

  71. Rubenstein JH, Inadomi JM, Scheiman J, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014;12(2):239–45.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Xinias I, Maris T, Mavroudi A, et al. Helicobacter pylori infection has no impact on manometric and pH-metric findings in adolescents and young adults with gastroesophageal reflux and antral gastritis: eradication results to no significant clinical improvement. Pediatr Rep. 2013;5(1):e3.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Wu JC, Chan FK, Wong SK, et al. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther. 2002;16(3):545–52.

    Article  PubMed  CAS  Google Scholar 

  74. Hirata K, Suzuki H, Matsuzaki J, et al. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. J Clin Biochem Nutr. 2013;52(2):172–8.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Yaghoobi M, Farrokhyar F, Yuan Y, et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010;105(5):1007–13.

    Article  PubMed  Google Scholar 

  76. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012;47(2):129–35.

    Article  PubMed  Google Scholar 

  77. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104 Suppl 2:S5–9.

    Article  PubMed  CAS  Google Scholar 

  78. Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: past, present and future. World J Gastrointest Pathophysiol. 2014;5(4):392–9.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Niv Y. H pylori recurrence after successful eradication. World J Gastroenterol. 2008;14(10):1477–8.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Sezikli M, Cetinkaya ZA, Guzelbulut F, et al. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori. J Clin Pharm Ther. 2012;37(3):282–5.

    Article  PubMed  CAS  Google Scholar 

  81. Sezikli M, Cetinkaya ZA, Sezikli H, et al. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? Helicobacter. 2009;14(4):280–5.

    Article  PubMed  CAS  Google Scholar 

  82. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134(4):937–44.

    Article  PubMed  CAS  Google Scholar 

  83. Momeni M, Katz JD. Mitigating GI risks associated with the use of NSAIDs. Pain Med. 2013;14(Suppl 1):S18–22.

    Article  PubMed  Google Scholar 

  84. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103(11):2890–907.

    Article  PubMed  CAS  Google Scholar 

  85. Gargallo CJ, Lanas A. Is NSAIDs-related gastrointestinal damage preventable? J Dig Dis. 2013;14(2):55–61.

    Article  PubMed  CAS  Google Scholar 

  86. Sakamoto Y, Shimoyama T, Nakagawa S, et al. Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs. Intern Med. 2014;53(11):1107–11.

    Article  PubMed  CAS  Google Scholar 

  87. Konturek PC, Kania J, Hahn EG, et al. Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase. J Physiol Pharmacol. 2006;57 Suppl 5:125–36.

    PubMed  Google Scholar 

  88. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Physician’s Desk Reference: PDR—Prevacid delayed-release capsules (TAP). PDR Electronic Library. June 18, 2008.

    Google Scholar 

  90. Physician’s Desk Reference: PDR—Nexium delayed-release capsules (AstraZeneca LP). PDR Electronic Library. June 18, 2008.

    Google Scholar 

  91. Physician’s Desk Reference: PDR—Zegerid powder for oral solution (Santarus). PDR Electronic Library. June 18, 2008.

    Google Scholar 

  92. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–60.

    Article  PubMed  CAS  Google Scholar 

  93. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157(1):148–5.

    Article  PubMed  CAS  Google Scholar 

  94. Tsukahara K, Kimura K, Morita S, et al. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J Cardiol. 2011;57(3):275–82.

    Article  PubMed  Google Scholar 

  95. Physician’s Desk Reference: PDR—Aciphex tablets (Eisai). PDR Electronic Library. June 18, 2008.

    Google Scholar 

  96. Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236–42.

    Article  PubMed  CAS  Google Scholar 

  97. Itoh S, Sekino Y, Shinomiya K, et al. The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. J Bone Miner Metab. 2013;31(2):206–11.

    Article  PubMed  CAS  Google Scholar 

  98. Roux C, Goldstein JL, Zhou X, et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int. 2012;23(1):277–84.

    Article  PubMed  CAS  Google Scholar 

  99. Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161–8.

    Article  PubMed  CAS  Google Scholar 

  100. de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989–98.

    Article  PubMed  CAS  Google Scholar 

  101. Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013;48(9):1016–22.

    Article  PubMed  CAS  Google Scholar 

  102. Tanaka M, Itoh S, Yoshioka T, et al. The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos. 2014;2014:607145.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Termanini B, Gibril F, Sutliff VE, et al. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104(5):422–30.

    Article  PubMed  CAS  Google Scholar 

  104. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422–8.

    Article  PubMed  Google Scholar 

  105. O’Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299–316.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Langan RC, Zawistoski KJ. Update on vitamin B12 deficiency. Am Fam Physician. 2011;83(12):1425–30.

    PubMed  Google Scholar 

  107. Lam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.

    Article  PubMed  CAS  Google Scholar 

  108. Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162–7.

    Article  PubMed  CAS  Google Scholar 

  109. Lechner K, Fodinger M, Grisold W, et al. Vitamin B12 deficiency. New data on an old theme. Wien Klin Wochenschr. 2005;117(17):579–91.

    Article  PubMed  CAS  Google Scholar 

  110. Force RW, Meeker AD, Cady PS, et al. Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother. 2003;37(4):490–3.

    Article  PubMed  CAS  Google Scholar 

  111. Evatt ML et al. Why vitamin B12 deficiency should be on your radar screen. http://www.cdc.gov/ncbddd/b12/index.html. 2011. CDC.

  112. Green R. Is it time for vitamin B-12 fortification? What are the questions? Am J Clin Nutr. 2009;89(2):712S–6S.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Wilhelm SM, Kale-Pradhan PB. Effects of proton pump inhibitors on vitamin B12. Maturitas. 2014;79(1):1–2.

    Article  PubMed  CAS  Google Scholar 

  114. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120(3):211–5.

    Article  PubMed  CAS  Google Scholar 

  115. Lewis JR, Barre D, Zhu K, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res. 2014;29(11):2489–97.

    Article  PubMed  Google Scholar 

  116. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27(11):1110–21.

    Article  PubMed  CAS  Google Scholar 

  117. Heaney RP. Bone as the Calcium Nutrient Reserve. In: Weaver CM, Heaney RP, editors. Calcium in Human Health. Totowa: Humana Press; 2006. p. 7–12.

    Chapter  Google Scholar 

  118. Weaver CM, Heaney RP. Introduction. In: Weaver CM, Heaney RP, editors. Calcium in Human Health. Totowa: Humana Press; 2006. p. 1–3.

    Chapter  Google Scholar 

  119. Awumey EM, Bukoski RD. Cellular Functions and Fluxes of Calcium. In: Weaver CM, Heaney RP, editors. Calcium in Human Health. Totowa: Humana Press; 2006. p. 13–35.

    Chapter  Google Scholar 

  120. Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. Physiol Rev. 2005;85(1):373–422.

    Article  PubMed  CAS  Google Scholar 

  121. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73(3):640–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Heaney RP, Recker RR, Weaver CM. Absorbability of calcium sources: the limited role of solubility. Calcif Tissue Int. 1990;46(5):300–4.

    Article  PubMed  CAS  Google Scholar 

  123. Heaney RP, Dowell SD, Bierman J, et al. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr. 2001;20(3):239–46.

    Article  PubMed  CAS  Google Scholar 

  124. Simonian HP, Vo L, Doma S, et al. Regional postprandial differences in pH within the stomach and gastroesophageal junction. Dig Dis Sci. 2005;50(12):2276–85.

    Article  PubMed  Google Scholar 

  125. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.

    Article  PubMed  CAS  Google Scholar 

  126. Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14(4):364–8.

    Article  PubMed  CAS  Google Scholar 

  127. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  128. Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10(8):1376–80.

    PubMed  CAS  Google Scholar 

  130. O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.

    Article  PubMed  CAS  Google Scholar 

  131. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79(2):76–83.

    Article  PubMed  CAS  Google Scholar 

  132. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.

    Article  PubMed  CAS  Google Scholar 

  133. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  135. Roux KJ, Crisp ML, Liu Q, et al. Nesprin 4 is an outer nuclear membrane protein that can induce kinesin-mediated cell polarization. Proc Natl Acad Sci U S A. 2009.

    Google Scholar 

  136. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Moberg LM, Nilsson PM, Samsioe G, et al. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas. 2014;78(4):310–5.

    Article  PubMed  CAS  Google Scholar 

  139. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13–9.

    Article  PubMed  CAS  Google Scholar 

  140. Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179(4):306–7.

    Article  PubMed  PubMed Central  Google Scholar 

  141. FDA. FDA: possible fracture risk with high dose, long-term use of proton pump inhibitors labeling changes will include new safety information. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm213377.htm. 2010.

  142. FDA Drug Safety Communication. FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. 2011.

  143. Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol. 1988;23(10):1259–66.

    Article  PubMed  CAS  Google Scholar 

  144. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther. 1990;4(2):131–8.

    Article  PubMed  CAS  Google Scholar 

  145. Sharara AI, El-Halabi MM, Ghaith OA, et al. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2013;62(4):518–26.

    Article  PubMed  CAS  Google Scholar 

  146. Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.

    Article  PubMed  CAS  Google Scholar 

  147. Maggio M, Lauretani F, Ceda GP, et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone. 2013;57(2):437–42.

    Article  PubMed  CAS  Google Scholar 

  148. Abrahamsen B, Vestergaard P. Proton pump inhibitor use and fracture risk—effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data. Bone. 2013;57(1):269–71.

    Article  PubMed  CAS  Google Scholar 

  149. Jo Y, Park E, Ahn SB, et al. A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver. 2014.

    Google Scholar 

  150. Ozdil K, Kahraman R, Sahin A, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013;33(9):2255–60.

    Article  PubMed  CAS  Google Scholar 

  151. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.

    Article  PubMed  CAS  Google Scholar 

  152. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.

    Article  PubMed  Google Scholar 

  153. Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res. 2014.

    Google Scholar 

  154. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007;370(9586):511–20.

    Article  PubMed  CAS  Google Scholar 

  155. Brody T. Inorganic nutrients. Nutritional biochemistry. London: Academic Press; 1999. p. 693–878.

    Book  Google Scholar 

  156. Hallberg L. Perspectives on nutritional iron deficiency. Annu Rev Nutr. 2001;21:1–21.

    Article  PubMed  CAS  Google Scholar 

  157. Hurrell RF, Reddy MB, Juillerat M, et al. Meat protein fractions enhance nonheme iron absorption in humans. J Nutr. 2006;136(11):2808–12.

    PubMed  CAS  Google Scholar 

  158. Henry EB, Carswell A, Wirz A, et al. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther. 2005;22(6):539–45.

    Article  PubMed  CAS  Google Scholar 

  159. Mowat C, Carswell A, Wirz A, et al. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology. 1999;116(4):813–22.

    Article  PubMed  CAS  Google Scholar 

  160. Cook JD, Brown GM, VALBERG LS. The effect of achylia gastrica on iron absorption. J Clin Invest. 1964;43:1185–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  161. Skikne BS, Lynch SR, Cook JD. Role of gastric acid in food iron absorption. Gastroenterology. 1981;81(6):1068–71.

    PubMed  CAS  Google Scholar 

  162. Bezwoda W, Charlton R, Bothwell T, et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92(1):108–16.

    PubMed  CAS  Google Scholar 

  163. Hashimoto R, Matsuda T, Chonan A. Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med. 2014;53(20):2297–9.

    Article  PubMed  Google Scholar 

  164. Khatib MA, Rahim O, Kania R, et al. Iron deficiency anemia: induced by long-term ingestion of omeprazole. Dig Dis Sci. 2002;47(11):2596–7.

    Article  PubMed  CAS  Google Scholar 

  165. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97(9):887–9.

    Article  PubMed  Google Scholar 

  166. Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.

    Article  PubMed  CAS  Google Scholar 

  167. Hutchinson C, Geissler CA, Powell JJ, et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  168. Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83–98.

    Article  PubMed  CAS  Google Scholar 

  169. Tempel M, Chawla A, Messina C, et al. Effects of omeprazole on iron absorption: preliminary study. Turk J Haematol. 2013;30(3):307–10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  170. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.

    Article  PubMed  CAS  Google Scholar 

  171. Van EC, Van LS, Marechal C, et al. Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. J Nephrol. 2014.

    Google Scholar 

  172. Lindner G, Funk GC, Leichtle AB, et al. Impact of proton pump inhibitor use on magnesium homoeostasis: a cross-sectional study in a tertiary emergency department. Int J Clin Pract. 2014;68(11):1352–7.

    Article  PubMed  CAS  Google Scholar 

  173. William JH, Nelson R, Hayman N, et al. Proton-pump inhibitor use is associated with lower urinary magnesium excretion. Nephrology (Carlton). 2014;19(12):798–801.

    Article  CAS  Google Scholar 

  174. Park CH, Kim EH, Roh YH, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014;9(11):e112558.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010;103(6):387–95.

    Article  PubMed  CAS  Google Scholar 

  176. Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med. 2011;171(15):1391–2.

    Article  PubMed  Google Scholar 

  177. FDA. FDA Drug Safety Communication: low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. 2011.

  178. Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85(6):295–330.

    Article  CAS  Google Scholar 

  179. Elitsur Y, Lawrence Z. Non-Helicobacter pylori related duodenal ulcer disease in children. Helicobacter. 2001;6(3):239–43.

    Article  PubMed  CAS  Google Scholar 

  180. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol. 1998;93(9):1409–15.

    PubMed  CAS  Google Scholar 

  181. Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol. 2006;163(11):1025–34.

    Article  PubMed  Google Scholar 

  182. Jang HJ, Choi MH, Shin WG, et al. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. Dig Dis Sci. 2008;53(6):1527–31.

    Article  PubMed  Google Scholar 

  183. Gisbert JP, Blanco M, Mateos JM, et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci. 1999;44(11):2295–302.

    Article  PubMed  CAS  Google Scholar 

  184. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab. 2008;93(2):363–71.

    Article  PubMed  CAS  Google Scholar 

  185. Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1083–94.

    Article  PubMed  Google Scholar 

  186. Kuipers EJ. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? Basic Clin Pharmacol Toxicol. 2006;99(3):187–94.

    Article  PubMed  CAS  Google Scholar 

  187. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother. 2002;36(5):812–6.

    Article  PubMed  Google Scholar 

  188. AstraZeneca. Prilosec Package Insert (omeprazole and omeprazole magnesium). Package Insert. 2009.

    Google Scholar 

  189. Physician’s Desk Reference: PDR—Protonix Tablets (Wyeth). PDR Electronic Library. June 18, 2008.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New Product Research, GI Health, GSK CH, 1500 Littleton Road, Parsippany, NJ, 07054, USA

    Ronit Zilberboim Ph.D.

  2. Consultants in Consumer Healthcare LLC, 53 Blackberry Lane, Morristown, 07960, NJ, USA

    Adrianne Bendich Ph.D., F.A.S.N., F.A.C.N.

Authors
  1. Ronit Zilberboim Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrianne Bendich Ph.D., F.A.S.N., F.A.C.N.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronit Zilberboim Ph.D. .

Editor information

Editors and Affiliations

  1. Consultants in Consumer Healthcare, Morristown, New Jersey, USA

    Adrianne Bendich

  2. Columbia University Inst. Human Nutrition, New York, New York, USA

    Richard J. Deckelbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zilberboim, R., Bendich, A. (2015). Gastric Acid Secretions, Treatments, and Nutritional Consequences. In: Bendich, A., Deckelbaum, R. (eds) Preventive Nutrition. Nutrition and Health. Springer, Cham. https://doi.org/10.1007/978-3-319-22431-2_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22431-2_29

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22430-5

  • Online ISBN: 978-3-319-22431-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation